Long Shortz with Imagion Biosciences: Key FDA milestone reached for MagSense

Long Shortz with Imagion Biosciences: Key FDA milestone reached for MagSense

Host Tylah Tully sits down with Imagion Biosystems (ASX:IBX) president of US Operations Ward Detwiler, who outlines the company’s mission to redefine how cancer is diagnosed through its MagSense molecular MRI platform. Detwiler explains how the first-in-class imaging agent brings molecular certainty to MRI scans and discusses the significance of lodging an Investigational New Drug application with the US FDA. The conversation also looks ahead to…

Medical-imaging company Imagion Biosystems Lodges IND with FDA for Phase 2 Trial of MagSense® HER2 targeted imaging agent

MELBOURNE, Australia--(BUSINESS WIRE)--$IBX #FDA--Imagion Biosystems, Ltd. (ASX: IBX) announced that the company has lodged an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its MagSense® targeted imagin... L'articolo Medical-imaging company Imagion Biosystems Lodges IND with FDA for Phase 2 Trial of MagSense® HER2 targeted imaging agent è un contenuto originale di 01net.